Aura Biosciences Announces Pricing of Public Offering of Common Stock
06 Noviembre 2023 - 9:02PM
Business Wire
Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage
biotechnology company developing a novel class of virus-like drug
conjugate (VDC) therapies for multiple oncology indications, today
announced the pricing of an underwritten public offering of
11,000,000 shares of its common stock at a price to the public of
$9.00 per share. The gross proceeds from the offering to Aura are
expected to be $99.0 million, before deducting underwriting
discounts and commissions and other offering expenses. The offering
is expected to close on or about November 9, 2023, subject to
customary closing conditions. In addition, Aura has granted the
underwriters a 30-day option to purchase up to 1,650,000 additional
shares of common stock at the public offering price, less the
underwriting discount.
Leerink Partners, TD Cowen and Evercore ISI are acting as joint
bookrunning managers for the offering. JMP Securities, A Citizens
Company, is acting as lead manager for the offering.
A shelf registration statement relating to the shares of common
stock offered in the public offering described above was filed with
the Securities and Exchange Commission (the “SEC”) on November 1,
2022 and declared effective by the SEC on November 7, 2022. The
offering is being made only by means of a written prospectus and
prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement and accompanying
prospectus relating to the offering has been filed with the SEC and
is available on the SEC’s website at www.sec.gov. A final
prospectus supplement and accompanying prospectus will be filed
with the SEC. When available, copies of the final prospectus
supplement and the accompanying prospectus may also be obtained by
contacting Leerink Partners LLC, Attention: Syndicate Department,
53 State Street, 40th Floor, Boston, MA 02109, by telephone at
(800) 808-7525, ext. 6105, or by email at syndicate@leerink.com;
Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus
Department, by telephone at (833) 297-2926, or by email at
PostSaleManualRequests@broadridge.com; or Evercore Group L.L.C.,
Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor,
New York, New York 10055; by telephone at (888) 474-0200, or by
email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company
developing VDCs, a novel class of therapies, for the treatment of
multiple oncology indications. Aura’s lead VDC candidate,
belzupacap sarotalocan (bel-sar; AU-011), consists of a virus-like
particle conjugated with an anti-cancer agent. Bel-sar is designed
to selectively target and destroy cancer cells and activate the
immune system with the potential to create long-lasting, anti-tumor
immunity. Bel-sar is currently in development for ocular cancers,
and Aura has initiated activities for the global Phase 3 trial
evaluating first-line treatment of early-stage choroidal melanoma,
a vision- and life-threatening form of eye cancer where the
standard of care with radiotherapy leaves patients with severe
comorbidities, including significant vision loss. Aura plans to
pursue development of bel-sar across its ocular oncology franchise
including for the treatment of patients with choroidal metastasis.
In addition, leveraging Aura’s technology platform, Aura is
developing bel-sar more broadly across multiple cancers, including
in patients with non-muscle invasive and muscle invasive bladder
cancer. Aura is headquartered in Boston, MA.
Forward-Looking Statements
Various statements in this release concerning the timing and
completion of the public offering on the anticipated terms or at
all may constitute forward-looking statements for the purposes of
the safe harbor provisions under the Private Securities Litigation
Reform Act of 1995, as amended, and other federal securities laws.
All such forward-looking statements are based on management’s
current expectations of future events and are subject to a number
of substantial risks and uncertainties, many of which are outside
Aura’s control, that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include
fluctuations in Aura’s stock price, changes in market conditions
and satisfaction of customary closing conditions related to the
public offering, as well as those risks more fully discussed in the
section entitled “Risk Factors” in the prospectus supplement and
registration statement referenced above, Aura’s Annual Report on
Form 10-K for the year ended December 31, 2022, filed on March 15,
2023 with the SEC and subsequent filings with the SEC including our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
There can be no assurance that Aura will be able to complete the
public offering on the anticipated terms. Accordingly, you should
not place undue reliance on these forward-looking statements. All
such statements speak only as of the date made, and Aura undertakes
no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events
or otherwise, unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106301238/en/
Investors and Media: Alex Dasalla Head of Investor
Relations and Corporate Communications
adasalla@aurabiosciences.com
Aura Biosciences (NASDAQ:AURA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Aura Biosciences (NASDAQ:AURA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024